{"id":1019933,"date":"2026-11-11T07:33:36","date_gmt":"2026-11-11T12:33:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/"},"modified":"2026-11-11T07:33:36","modified_gmt":"2026-11-11T12:33:36","slug":"dyne-therapeutics-to-participate-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/","title":{"rendered":"Dyne Therapeutics to Participate in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., Nov.  11, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2I0FlSilLHNuwZGvIr5hPeecAuHBieMZJlDjJ9rYhtCEogIC2IpFQgKd_gzytL50hqHzliexfYNJxDbesdJB6glzxip8zPviFwhoiRXTEBo=\" rel=\"nofollow\" target=\"_blank\"><u>Dyne Therapeutics, Inc<\/u><\/a>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Jefferies Global Healthcare Conference<\/strong>, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London<\/li>\n<\/ul>\n<p>A live webcast of the fireside chat will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cM9Q57Bm592gidz_3LVKoq9EE5iZwAvPZsWRq6JHHxw7IOg9nq75KBiYUoFJG0bELsqmx_4dKyZdboODmKBDOi0Ze0XnRUEMxaXKyrVftol-unbut9sYpkkBK9BfAoITHQK3yfFu9dgS2L78S9xCGEBCrZ3A6VGgKiqz0MhjVUBMgNZfA3aHbA_QAZyfFpe4YtkzGHdu57tqMYdJ1GWNqd1TFI9Tws6kmsX8lrGilnsMYtYx1-1McDBwEo639ikKlsWEKHnvv73wnTyS2lwNysZXsncI6iA8h5QH10hIGlWGJLip--OyKCg64eacwfIDJYJhHxxWk8ZwTz4X0BjhqTa5YF_zUOjIeByXiJ7DyTnC8DqtM1gHWSWh5ziynaL9KGNbse-HbHKIRdaWTF8qoHwqOHSbGKycBdFy6926MuYvNPOCyZ1X3ErGAUZK0cA7Ziv271tvVBafcpzlqeXo8FwElqljTPDa7Rb199UzHi8m9MfJraV4uEmLcEFtZaHz6lwH79B1NgwN9as2Lwcjj7w_-BkQ93d732Z3UCe1iIa23fkrjd0-deueJCM8jUr4-Ya-k3dxewR3ZsTN3H2y8S9vwmOoAlZDFHTq52p4ohpjFIa50e5z-SAUT7tXNRSDWztF3kIY4l0VNS_1hecx8qX19xszeOaWTK1FLzUSjKDVg7opXeH_d_cCCHXMsTRahV2iMJ1CGqI2nVf1F3Ucb9sOd9-DiUOHVtOpVKDZhxvFSdOjtGYyaTrNyquX1Fq92Z_pXqFgsAR6CXFKM3AIclEgGTOMA00OeozkllKrDpppD3hDJqXmkIZu_2iGQn6WwSy1L2ik6dvjVO97WeDDmmkDHj_Ffp3OojY1zQP3TGg=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a>\u00a0and a replay will be accessible for 90 days.<\/p>\n<p>\n        <strong>About Dyne Therapeutics<\/strong>\n      <\/p>\n<p>Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cM9Q57Bm592gidz_3LVKoim0IgMKgp7FFaRkgNzhCGuy-lx-ufHfq2XlYex5FWQI12jY_BpKeXZ59tQqvOALZmS2BB_zCy38q5ulhuTCSlY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.dyne-tx.com\/<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yzmvLoOBvgNCY85Fdrowb5QHSjZbkLeW6WwN0NGnC-WS03c-bI15xhcENl5nvz_TsED-8DqI09jIN53cVlDeBA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LiDsNtZQ84gHwrUETvPbPTpv7CYlR7ALkcR_-UY_7HbuK7Z7x3bvM6P-Wtbx2RZwRweiBztYJ0Hm0Kav-YPUJLMH-QZjVxPsB4xG_80tQVw=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1m3-xWLWxUgywoB6pl3rCETYqVBvWo_bTuMycEw5rToPlVYOSHG9Hryc3-RpzXc3MA60_iEvoZd9wYZ_hTlO-HcTfpqWWXVt2ZedWVS3_sQ=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Mia Tobias<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IZoqzH6jS6rFnm23nalbUFJ0voUhKllhHSpI6xfs3s3XmioQtqW2A88-5onoF3QVYJquMTP8QLisu2dJo54f5g==\" rel=\"nofollow\" target=\"_blank\">ir@dyne-tx.com<\/a><br \/>781-317-0353<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Stacy Nartker\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5gAR7fU4TxHpZSKXERb2kg8hg3NjH1NpwqOj86eG64Eaw12WO4zCXbO59sPm3as3c3HbyZM26riuaAR3zi_ws5Us8NeEbE-LM8jRjxNhW-k=\" rel=\"nofollow\" target=\"_blank\">media@dyne-tx.com<\/a><br \/>781-317-1938<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmVjNjdjODItMTc2MS00NmYxLWJjNTctNGQ1OWQzMWMwNzVmLTEyMTI0NDUtMjAyNi0xMS0xMS1lbg==\/tiny\/Dyne-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference: Jefferies Global Healthcare Conference, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London A live webcast of the fireside chat will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyne Therapeutics to Participate in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019933","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference: Jefferies Global Healthcare Conference, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London A live webcast of the fireside chat will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central &hellip; Continue reading &quot;Dyne Therapeutics to Participate in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T12:33:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Participate in Upcoming Investor Conference\",\"datePublished\":\"2026-11-11T12:33:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/\"},\"wordCount\":221,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/\",\"name\":\"Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\",\"datePublished\":\"2026-11-11T12:33:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Participate in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference: Jefferies Global Healthcare Conference, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London A live webcast of the fireside chat will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central &hellip; Continue reading \"Dyne Therapeutics to Participate in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-11T12:33:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Participate in Upcoming Investor Conference","datePublished":"2026-11-11T12:33:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/"},"wordCount":221,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/","name":"Dyne Therapeutics to Participate in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=","datePublished":"2026-11-11T12:33:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTE0NyM3OTU5MDU0IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-participate-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Participate in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019933"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}